Target intelligence / Profile preview

DHHC protein acyltransferase (DHHC-PAT)

Target
DHHC-PAT
Molecular classification
Enzyme, Protein acyltransferase, S-acyltransferase, Multi-pass transmembrane protein
01

Overview

DHHC protein acyltransferases are a family of enzymes responsible for the post-translational modification known as S-acylation (commonly palmitoylation), in which a long-chain fatty acid such as palmitate is covalently attached to cysteine residues of substrate proteins via a thioester bond. The family is defined by a conserved Asp-His-His-Cys (DHHC) cysteine-rich domain motif, which is essential for its enzymatic activity. These multipass transmembrane proteins localize mainly to intracellular membranes and play crucial roles in regulating protein localization, stability, and function by modulating the membrane association of numerous signaling proteins. In humans, there are 23 known DHHC genes, each with specificity for different substrates. Dysregulation or mutation of DHHC acyltransferases has been implicated in diverse diseases including cancers and neurodegenerative disorders. Their essential biological functions and links to disease make them an emerging class of therapeutic targets, but specific, clinically useful modulators remain in early development.

Other names
DHHC S-acyltransferasePalmitoyltransferaseProtein acyltransferase (PAT)ZDHHC (gene/protein nomenclature, e.g., ZDHHC20)
02

Mechanism of action

Inhibition of acyltransferase (palmitoyltransferase) activity, usually by competitive or covalent inhibition of the active site cysteine

03

Biological functions

Protein palmitoylation (S-acylation)Post-translational modificationRegulation of protein traffickingMembrane localizationSignal transduction
04

Disease associations

CancerNeurodegenerative diseaseOther (notably, additional roles suspected as family is large and not all members have been characterized)
05

Safety considerations

Lack of isoform-selective inhibitors (many inhibitors, such as 2-bromopalmitate, are non-selective and can disrupt essential palmitoylation broadly)Potential for off-target effects impacting diverse cell functions due to broad role in protein trafficking and signaling
06

Interacting drugs

2-bromopalmitate (broad-spectrum S-acylation inhibitor, non-selective)

1 more in the full profile.

07

Biomarkers

No widely validated clinical biomarkers for DHHC acyltransferase activity are established; dysregulation in DHHC expression/palmitoylation patterns can be detected by proteomic or genetic analyses in research contexts

Beyond the preview

Go deeper on DHHC protein acyltransferase (DHHC-PAT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DHHC protein acyltransferase (DHHC-PAT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call